We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current AKRO market cap is 1.22B. The company's latest EPS is USD -2.6957 and P/E is -8.02.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -36.09M | -25.42M | -28.75M | -35.63M | -46.62M |
| Net Income | -35.54M | -23.06M | -25.83M | -31.08M | -39.66M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -45.65M | -80.15M | -100.89M | -115.16M | -172.87M |
| Net Income | -43.76M | -79.21M | -100.78M | -112.03M | -151.76M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 379.41M | 356.57M | 348.82M | 663.81M | 635.33M |
| Total Liabilities | 35.9M | 30.01M | 42.47M | 47.37M | 52.2M |
| Total Equity | 343.51M | 326.56M | 306.35M | 616.44M | 583.14M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 138.12M | 273.34M | 195.55M | 356.57M | 580.27M |
| Total Liabilities | 9.39M | 14.63M | 26.44M | 30.01M | 44.97M |
| Total Equity | 128.73M | 258.71M | 169.11M | 326.56M | 535.31M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -67.01M | -92.52M | -24.63M | -47.02M | -96.74M |
| Investing | 37.62M | -63.83M | 17.59M | -110.71M | -236.41M |
| Financing | 252.91M | 255.63M | 15.15M | 352.01M | 352.81M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -35.63M | -70.8M | -79.68M | -92.52M | -145.37M |
| Investing | -71.51M | -9.76M | 42.28M | -63.83M | -223.62M |
| Financing | 95.99M | 203.11M | 602k | 255.63M | 353.32M |
| Market Cap | 1.22B |
| Price to Earnings Ratio | -8.02 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 5.2 |
| Price to Book Ratio | 2.27 |
| Dividend Yield | - |
| Shares Outstanding | 56.3M |
| Average Volume (1 week) | 796.1k |
| Average Volume (1 Month) | 840.67k |
| 52 Week Change | -43.46% |
| 52 Week High | 58.38 |
| 52 Week Low | 11.25 |
| Spread (Intraday) | 0.55 (2.55%) |
| Company Name | Akero Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.akerotx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
